Tobramycin SulfateCAS# 49842-07-1 |
- Valproic acid sodium salt (Sodium valproate)
Catalog No.:BCC2156
CAS No.:1069-66-5
- Vorinostat (SAHA, MK0683)
Catalog No.:BCC2145
CAS No.:149647-78-9
- Resminostat (RAS2410)
Catalog No.:BCC2165
CAS No.:864814-88-0
- PCI-34051
Catalog No.:BCC2148
CAS No.:950762-95-5
- Droxinostat
Catalog No.:BCC2157
CAS No.:99873-43-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 49842-07-1 | SDF | Download SDF |
| PubChem ID | 62005 | Appearance | Powder |
| Formula | C18H39N5O13S | M.Wt | 565.59 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | <5.66mg/mL in DMSO | ||
| Chemical Name | (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid | ||
| SMILES | C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(CC(C(O3)CN)O)N)N.OS(=O)(=O)O | ||
| Standard InChIKey | ZEUUPKVZFKBXPW-TWDWGCDDSA-N | ||
| Standard InChI | InChI=1S/C18H37N5O9.H2O4S/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18;1-5(2,3)4/h5-18,24-28H,1-4,19-23H2;(H2,1,2,3,4)/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Tobramycin Sulfate Dilution Calculator
Tobramycin Sulfate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.7681 mL | 8.8403 mL | 17.6807 mL | 35.3613 mL | 44.2016 mL |
| 5 mM | 0.3536 mL | 1.7681 mL | 3.5361 mL | 7.0723 mL | 8.8403 mL |
| 10 mM | 0.1768 mL | 0.884 mL | 1.7681 mL | 3.5361 mL | 4.4202 mL |
| 50 mM | 0.0354 mL | 0.1768 mL | 0.3536 mL | 0.7072 mL | 0.884 mL |
| 100 mM | 0.0177 mL | 0.0884 mL | 0.1768 mL | 0.3536 mL | 0.442 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Ethyl Nipecotate
Catalog No.:BCC3272
CAS No.:5006-62-2
- Scopine
Catalog No.:BCN1940
CAS No.:498-45-3
- 1,6-Anhydro-β-D-glucose
Catalog No.:BCC8427
CAS No.:498-07-7
- Acetovanillone
Catalog No.:BCN2916
CAS No.:498-02-2
- Vanillyl alcohol
Catalog No.:BCN3832
CAS No.:498-00-0
- AEE788 (NVP-AEE788)
Catalog No.:BCC2520
CAS No.:497839-62-0
- 11beta-Hydroxylupeol
Catalog No.:BCN7571
CAS No.:49776-92-3
- Stiripentol
Catalog No.:BCC3977
CAS No.:49763-96-4
- H-D-Phe(4-Me)-OH
Catalog No.:BCC3271
CAS No.:49759-61-7
- Dobutamine hydrochloride
Catalog No.:BCC5391
CAS No.:49745-95-1
- Tupichinol A
Catalog No.:BCN7697
CAS No.:497142-88-8
- DC_AC50
Catalog No.:BCC6488
CAS No.:497061-48-0
- EX 527 (SEN0014196)
Catalog No.:BCC2223
CAS No.:49843-98-3
- Erythroskyrin
Catalog No.:BCN1836
CAS No.:4987-27-3
- Corydamine
Catalog No.:BCN3366
CAS No.:49870-84-0
- IsoMaltose
Catalog No.:BCN8321
CAS No.:499-40-1
- beta-Thujaplicin
Catalog No.:BCN3895
CAS No.:499-44-5
- 5-Isopropyl-2-methylphenol
Catalog No.:BCN2633
CAS No.:499-75-2
- 2,4-Pyridinedicarboxylic Acid
Catalog No.:BCC6483
CAS No.:499-80-9
- Tioxolone
Catalog No.:BCC2316
CAS No.:4991-65-5
- Guanidine HCl
Catalog No.:BCC4785
CAS No.:50-01-1
- Dexamethasone (DHAP)
Catalog No.:BCC1184
CAS No.:50-02-2
- Cortisone acetate
Catalog No.:BCC4771
CAS No.:50-04-4
- Mitomycin C
Catalog No.:BCC2388
CAS No.:50-07-7
Clinical application of tobramycin-impregnated calcium sulfate beads in six dogs (2002-2004).[Pubmed:18981197]
J Am Anim Hosp Assoc. 2008 Nov-Dec;44(6):320-6.
Medical records for six dogs treated with tobramycin-impregnated calcium sulfate beads were reviewed for indications, duration of disease, number of beads implanted, complications, radiographic appearance of the beads, and outcomes. Beads were no longer visible on radiographs made 5 weeks after implantation. Osteomyelitis resolved in five of five dogs with follow-up. The lack of complications and the resolution of clinical signs associated with tobramycin calcium sulfate bead implantation support their clinical application in treating osteomyelitis.
Purity determination of amphotericin B, colistin sulfate and tobramycin sulfate in a hydrophilic suspension by HPLC.[Pubmed:25828728]
J Chromatogr B Analyt Technol Biomed Life Sci. 2015 May 15;990:7-14.
A suspension comprising of the three antibiotic substances amphotericin B, colistin sulfate and Tobramycin Sulfate is often used in clinical practice for the selective decontamination of the digestive tract of patients in intensive care. Since no detailed procedures, specifications or stability data are available for manufacturing this suspension, there may be discrepancies regarding formulation and stability of suspensions prepared in different pharmacies. The aim of this work is to develop a standardized formulation and to determine its stability under defined storage conditions. This would help guarantee that all patients receive the same preparation, therefore ensuring similar efficacy and improved safety. The first step in this process is to develop the required analytical tools to measure the content and purity of the drug substances in this complex mixture. In this paper, the development and validation of these tools as well as the development of the drug suspension formulation is described. The formulation comprises of Ampho-Moronal((R))-Suspension (Dermapharm) and a buffered, preservated aqueous solution of colistin sulfate and Tobramycin Sulfate. Two simple, well established high-performance liquid chromatography (HPLC) methods in the European Pharmacopoeia (EP) for impurity profiling of the two active ingredients amphotericin B and colistin sulfate were combined with a newly developed sample extraction procedure for the suspension. Sufficient selectivity and stability-indicating power have been demonstrated. Additionally, a new robust routine method was developed to determine possible degradation products of Tobramycin Sulfate in the investigated suspension. The specificity, precision, accuracy and linearity of the analytical procedures were demonstrated. The recovery rate was in the range of 90-110%. The precision results for the calculated impurities showed variation coefficients of <10%. The calibration curves were found to be linear with correlation of greater than 0.9994 for all components. The results show the suitability of the methods for the quality control analysis of the suspension.
Tobramycin exposure from active calcium sulfate bone graft substitute.[Pubmed:24593819]
BMC Pharmacol Toxicol. 2014 Mar 4;15:12.
BACKGROUND: Bone graft substitute such as calcium sulfate are frequently used as carrier material for local antimicrobial therapy in orthopedic surgery. This study aimed to assess the systemic absorption and disposition of tobramycin in patients treated with a tobramycin-laden bone graft substitute (Osteoset(R) T). METHODS: Nine blood samples were taken from 12 patients over 10 days after Osteoset(R) T surgical implantation. Tobramycin concentration was measured by fluorescence polarization. Population pharmacokinetic analysis was performed using NONMEM to assess the average value and variability (CV) of pharmacokinetic parameters. Bioavailability (F) was assessed by equating clearance (CL) with creatinine clearance (Cockcroft CLCr). Based on the final model, simulations with various doses and renal function levels were performed. (ClinicalTrials.gov number, NCT01938417). RESULTS: The patients were 52 +/- 20 years old, their mean body weight was 73 +/- 17 kg and their mean CLCr was 119 +/- 55 mL/min. Either 10 g or 20 g Osteoset(R) T with 4% Tobramycin Sulfate was implanted in various sites. Concentration profiles remained low and consistent with absorption rate-limited first-order release, while showing important variability. With CL equated to CLCr, mean absorption rate constant (ka) was 0.06 h-1, F was 63% or 32% (CV 74%) for 10 and 20 g Osteoset(R) T respectively, and volume of distribution (V) was 16.6 L (CV 89%). Simulations predicted sustained high, potentially toxic concentrations with 10 g, 30 g and 50 g Osteoset(R) T for CLCr values below 10, 20 and 30 mL/min, respectively. CONCLUSIONS: Osteoset(R) T does not raise toxicity concerns in subjects without significant renal failure. The risk/benefit ratio might turn unfavorable in case of severe renal failure, even after standard dose implantation.
A Microfluidic Approach to Investigating a Synergistic Effect of Tobramycin and Sodium Dodecyl Sulfate on Pseudomonas aeruginosa Biofilms.[Pubmed:26753708]
Anal Sci. 2016;32(1):67-73.
In recent years, a microfluidic technology has contributed a significant role in biological research, specifically for the study of biofilms. Bacterial biofilms are a source of infections and contamination in the environment due to an extra polymeric matrix. Inadequate uses of antibiotics make the bacterial biofilms antibiotic resistant. Therefore, it is important to determine the effective concentration of antibiotics in order to eliminate bacterial biofilms. The present microfluidic study was carried out to analyze the activities of tobramycin and sodium dodecyl sulfate (SDS) against Pseudomonas aeruginosa biofilms with a continuous flow in order to achieve a greater delivery of the agents. The results show that a co-treatment of tobramycin and SDS significantly reduced the biomass of biofilms (by more than 99%) after 24 h. Tobramycin and SDS killed and detached bacteria in the cores of biofilms. Evidently, our data suggest that a microchannel would be effective for both quantitative and qualitative evaluations in order to test combinatorial effect of drugs and chemicals on a complexed biological system including biofilm.
